Survival of COVID-19 Patients Who Received Antiviral and Antiviral Therapy Combined with Anti-inflammation Therapy in a National Referral Hospital, Indonesia
DOI:
https://doi.org/10.3889/oamjms.2022.8328Keywords:
COVID-19, Survival analysis, Antiviral, Anti-inflammatory, OutcomeAbstract
Background: COVID-19 has infected and spread over the whole earth. For the time being, there is no cure for COVID 19. Although several medications have the potential to be utilized at various stages of the disease, no therapy has yet been demonstrated to be completely successful.
Aim: This study aims to determine survival of COVID-19 patients who received antiviral and antiviral therapy combined with anti-inflammation therapy in a national referral hospital Indonesia.
Methods: COVID-19 patients treated at Dr. M Djamil General Hospital in Padang, Indonesia were the subject of an analytic investigation using a retrospective cohort design. From January to June 2021, data was gathered from patient medical records. Independent sample T test and Chi-square test were used to analyze subject characteristics data. The median survival and survival rates were calculated using Kaplan-Meier survival analysis. It is also subjected to cox-regression analysis in order to answer the study hypothesis.
Results: The mean age of the subjects who received antiviral and anti-inflammatory medication was 60.95 12.11 years, while the average age of those who received antiviral therapy was 56.72 17.80 years, with the highest sex being male in both groups (59.3 percent ; 50.6 percent ). Antiviral and antiviral medication, as well as anti-inflammatory therapy, had no effect on the length of stay of COVID-19 patients (p>0.05). Antiviral and antiviral therapy, as well as anti-inflammatory therapy, play a role in the outcome of COVID-19 patients (p<0.05), with patients receiving antiviral and anti-inflammatory therapy being a preventive factor in the final outcome of patients compared to patients receiving antiviral therapy HR = 0.69 (95% CI 0.48-0.99).
Conclusion: When compared to patients who just got antiviral medication, patients who received antiviral plus anti-inflammatory therapy had a better outcome.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Majumder J, Minko T. Recent developments on therapeutic and diagnostic approaches for COVID-19. AAPS J. 2021;23(1):14. https://doi.org/10.1208/s12248-020-00532-2 PMid:33400058 DOI: https://doi.org/10.1208/s12248-020-00532-2
Tsatsakis A, Calina D, Falzone L, Petrakis D, Mitrut R, Siokas V, et al. COVID-19pathophysiology and its clinical implications: An integrative overview of the pharmacotherapeutic management of COVID-19. Food Chem Toxicol. 2020;146:111769. https://doi.org/10.1016/j.fct.2020.111769 PMid:32979398 DOI: https://doi.org/10.1016/j.fct.2020.111769
Varghese PM, Tsolaki AG, Yasmin H, Shastri A, Ferluga J, Vatish M, et al. Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies. Immunobiology. 2020;225(6):152008. https://doi.org/10.1016/j.imbio.2020.152008 PMid:33130519 DOI: https://doi.org/10.1016/j.imbio.2020.152008
Dhama K, Khan S, Tiwari R, Sircar S, Bhat S, Malik YS, et al. Coronavirus disease 2019-COVID-19. Clin Microbiol Rev. 2020;33(4):e00028-20. https://doi.org/10.1128/CMR.00028-20 PMid:32580969 DOI: https://doi.org/10.1128/CMR.00028-20
WHO Coronavirus Disease (COVID-19) Dashboard. Geneva: WHO. Accessed from: https://www.covid19.who.int/table [Last accessed 2021 Dec 10].
Cao YC, Deng QX, Dai SX. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence. Travel Med Infect Dis. 2020;35:101647. https://doi.org/10.1016/j.tmaid.2020.101647 PMid:32247927 DOI: https://doi.org/10.1016/j.tmaid.2020.101647
Zhang J, Wang M, Zhao M, Guo S, Xu Y, Ye J, et al. The clinical characteristics and prognosis factors of mild-moderate patients with COVID-19 in a mobile cabin hospital: A retrospective, single-center study. Front Public Health. 2020;8:264. https://doi.org/10.3389/fpubh.2020.0026 PMid:32582615 DOI: https://doi.org/10.3389/fpubh.2020.00264
Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020;382(24):2327-36. https://doi.org/10.1056/NEJMoa2007016 PMid:32275812 DOI: https://doi.org/10.1056/NEJMc2015312
Chugh H, Awasthi A, Agarwal Y, Gaur RK, Dhawan G, Chandra R. A comprehensive review on potential therapeutics interventions for COVID-19. Eur J Pharmacol. 2021;890:173741. https://doi.org/10.1016/j.ejphar.2020.173741 PMid:33227287 DOI: https://doi.org/10.1016/j.ejphar.2020.173741
Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol. 2020;215:108427. https://doi.org/10.1016/j.clim.2020.108427 PMid:32325252 DOI: https://doi.org/10.1016/j.clim.2020.108427
Deftereos SG, Giannopoulos G, Vrachatis DA, Siasos GD, Giotaki SG, Gargalianos P, et al. Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with Coronavirus disease 2019: The GRECCO-19 randomized clinical trial. JAMA Netw Open. 2020;3(6):2013136. https://doi.org/10.1001/jamanetworkopen.2020.13136 PMid:32579195 DOI: https://doi.org/10.1001/jamanetworkopen.2020.13136
Lopes MI, Bonjorno LP, Giannini MC, Amaral NB, Menezes PI, Dib SM, et al. Beneficial effects of colchicine for moderate to severe COVID-19: A randomised, double-blinded, placebo-controlled clinical trial. RMD Open. 2021;7(1):e001455. https://doi.org/10.1136/rmdopen-2020-001455 PMid:33542047 DOI: https://doi.org/10.1136/rmdopen-2020-001455
Scarsi M, Piantoni S, Colombo E, Airó P, Richini D, Miclini M, et al. Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID19 pneumonia and acute respiratory distress syndrome. Ann Rheum Dis. 2020;79(10):1286-9. https://doi.org/10.1136/annrheumdis-2020-217712 PMid:32732245 DOI: https://doi.org/10.1136/annrheumdis-2020-219787
Brunetti L, Diawara O, Tsai A, Firestein BL, Nahass RG, Poiani G, et al. Colchicine to weather the cytokine storm in hospitalized patients with COVID-19. J Clin Med. 2020;9(9):2961. https://doi.org/10.3390/jcm9092961 PMid:32937800 DOI: https://doi.org/10.3390/jcm9092961
Mehta KG, Patel T, Chavda PD, Patel P. Efficacy and safety of colchicine in COVID-19: A meta-analysis of randomised controlled trials. RMD Open. 2021;7(3):e001746. https://doi.org/10.1136/rmdopen-2021-001746 PMid:34810227 DOI: https://doi.org/10.1136/rmdopen-2021-001746
Golpour M, Mousavi T, Alimohammadi M, Mosayebian A, Shiran M, Navaei RA, et al. The effectiveness of Colchicine as an anti-inflammatory drug in the treatment of Coronavirus disease 2019: Meta-analysis. Int J Immunopathol Pharmacol. 2021;35:1-8. https://doi.org/10.1177/20587384211031763 PMid:34250834 DOI: https://doi.org/10.1177/20587384211031763
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 Afriani Afriani, Sabrina Ermayanti, Irvan Medison, Russilawati Russilawati, Fenty Anggrainy, Yessy Susanty Sabri, Ricvan Dana Nindrea (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
